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Abstract
Fourteen drugs have been removed from the market worldwide due to
an increased risk of torsade de pointes (TdP), a potentially fatal ven-
tricular arrhythmia. Almost all of the removed drugs that have been
linked to an increased risk for TdP have been shown to block the hu-
man ether-à-go-go-related gene (hERG) potassium channel. In addition,
block of the hERG potassium channel results in a prolongation of the
duration of ventricular repolarization measured as the QT interval on
the electrocardiogram (ECG).
Therefore, almost all new drugs must be studied in a thorough QT
(TQT) study to determine if they have the potential to prolong the heart
rate corrected QT interval (QTc). The TQT study is an expensive study
that in addition to including a negative control (placebo), also includes
a positive pharmacologic control to ensure assay sensitivity and proper
study conduct.
Not all drugs that block the hERG potassium channel and prolong
the QTc interval have been linked with a risk for TdP likely due to
additional inward current block. For example block of the late sodium
(amiodarone, ranolazine) or L-type calcium (verapamil). In addition,
not every study is able to detect the QTc prolongation associated with
the positive pharmacological control. It is unknown which factors have
a greater influence on study quality and the ability to demonstrate assay
sensitivity.
TQT studies from the Food and Drug Administration (FDA) ECG-
Warehouse were used to investigate factors of assay sensitivity and how
they relate to ECG quality metrics, as well as new ECG biomarkers that
could complement the QTc interval and increase specificity of the TQT
study. In addition, two prospective clinical trials were conducted to
evaluate the performance of the new ECG biomarkers. The first clinical
trial focuses on comparing selective hERG potassium channel blockers to
multichannel blockers. The goal of the second clinical trial is to evaluate
v
if selective late sodium or L-type calcium channel blockers could reduce
drug-induced QTc prolongation. Finally, data from the first clinical trial
was used to study dynamic ECG biomarkers.
The retrospective analysis of TQT studies showed that the most
influential factors of assay sensitivity is reader variability and stability
of heart rate. The latter being driven in part by study conduct. In
addition, the retrospective analysis suggested that by breaking down
the QTc interval into QRS, J-Tpeakc and Tpeak-Tend intervals that it is
possible to detect the presence of inward current block (late sodium or
L-type calcium), that can reduce the risk for TdP.
In two prospective clinical studies the proposed ECG biomarkers
were shown to be able to detect the presence of inward current block.
Moreover, the second clinical trial showed that a selective late sodium
current blocker (mexiletine or lidoacaine) shortens dofetilide-induced
QTc prolongation. Lastly, using ECG measurements from periods of
postural maneuvers and light exercises it was possible to detect the pres-
ence of reverse use dependence and increased instability of the QT inter-
val (dynamic ECG biomarkers) associated with hERG potassium chan-
nel block. No changes in the dynamic ECG biomarkers was observed
with ranolazine, and only small changes was observed with verapamil.
Overall, the findings in this thesis show that by ensuring consistently
measured QT intervals and maximizing heart rate stability the ability
to detect the QTc interval prolongation associated with the positive con-
trol is improved. Ensuring consistent QT measurements also results in
improved quality of QTc measurements, quantified using QTc quality
metrics. In addition, the use of the J-Tpeakc and Tpeak-Tend intervals
allows for discrimination between drugs that are selective hERG potas-
sium channel blockers, and are associated with a high risk for TdP, and
multichannel blockers with a low risk for TdP.
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CHAPTER 1
Introduction
The main focus of this thesis is centered around the clinical evalu-
ation of drug-induced effects on cardiac ventricular repolarization.
Cardiac ventricular repolarization can be quantified by measuring
the QT interval on the electrocardiogram (ECG). More specifi-
cally, this thesis focuses on factors of ECG data quality in clini-
cal QT studies or the so-called thorough QT (TQT) studies and
the use of new ECG biomarkers to enhance assessment of drug-
induced effects.
This introduction starts with a description of the basis of the
ECG waveforms and their relationship to the cardiac action po-
tential. Then, the measurement of the QT interval and correc-
tion for heart rate effects is described. After describing the ECG
waveforms and the QT interval, the history of congenital long
QT syndrome is described as well as the acquired or drug-induced
long QT syndrome and the regulatory response to the discovery
of drug-induced long QT. Following the description of the regula-
tory response, methods for evaluating cardiac repolarization are
described using either preclinical assays or the TQT study will be
discussed. Finally, the introduction of this thesis concludes with a
discussion of the limitations and shortcomings of the TQT study
and recent advances to address these limitations.
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1.1 The Cardiac Action Potential
The shape of the ECG waveforms results from the sum of the cur-
rent flow from all action potentials of the cardiac cells across the
heart. Thus, it partly reflects the cellular cardiac action potential
and partly the effect of propagating electrical activity in the heart.
The cardiac action potential (Figure 1.1) can be divided into
five phases (0 through 4). Phase 0 is the upstroke of the action
potential and is primarily driven by the inward sodium ion current
(INa). Phase 1 is the termination of the upstroke and early repolar-
ization as a result of inactivation of the sodium channels and acti-
vation of the transient outward potassium ion current (Ito). Phase
2, also known as the plateau phase, reflects a balance between the
inward L-type calcium ion flow (ICa,L) and outward potassium ion
repolarization currents (IK). A small late sodium current (INa,L)
is also present. Phase 3 is the final repolarization phase, which is
driven by the rapid (IKr) and slow (IKs) potassium currents. The
human ether-à-go-go-related gene (hERG) potassium ion channel
is one of the main drivers of the IKr current, which is one of the
most critical currents for cardiac safety pharmacology. The chan-
nel was first identified in fruit flies, where blockage of the channel
resulted in movements that reminded the investigators of the go-
go dance.1 The final phase of the cardiac action potential is phase
4, where the inward rectifier potassium ion current (IK1) is active,
which is responsible for restoring the resting potential.
1.2 The Waveforms on the Electrocardiogram
In 1887, Waller recorded the first human ECG.3 The recording
showed two deflections corresponding to two ventricular events.
Waller, who was a physiologist, named them V1 and V2, pre-
sumably based on the anatomical parts of the heart associated
with the events.4 Later improvements in the electrometers allowed
recording of the atrial excitation. While Waller labeled the atrial
waveform as A, Einthoven, who was a mathematician, named it as
P.5 Although the reason for selecting P is not clear, it seems that
2
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Figure 1.1 Overview of the genesis of the electrocardiogram (ECG)
(adapted from2). The left panel (A) shows the relationship between
the different leads (I,II, III, aVR, aVL, AVF and V1-6) and electrodes
(RA: right arm, LA: left arm, LF: left foot). The triangle with the three
limb leads (I, II and III) is also called Einthoven’s triangle. The right
panel (B) shows a ventricular action potential and how it relates to the
ECG (lead II). The numbers on the action potential denotes the different
phases of the action potential (see text) and the arrows denotes if the
currents are inward (pointing inside the action potential) or outward
currents. Na: Peak sodium (INa), Ca: L-type calcium (ICa,L), Na,L:
Late sodium (INa,L), K: potassium (Ik).
the mathematician was thinking about Descartes’ use of the letter
P to designate a point on a curve.4 The complete understanding
on how the predominant ECG events and waveforms came to be
named may not be completely certain, but Einthoven’s conven-
tion,4 where the ECG consists primarily of five distinct waveforms
(P, Q, R, S, and T-waves [Figure 1.1]) has become the dominant
naming convention.
Different leads can be thought of as looking at the electrical
activity of the heart (generated by the currents described earlier)
from different angles. The initial set of leads, leads I-III, were pro-
3
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posed by Einthoven in 1912.6 Wilson and colleagues investigated
in the 1930s how unipolar potentials could be recorded,7,8 result-
ing in three additional limb leads VR,VL and VF . In 1942 Gold-
berger proposed an augmented version of these signals the aVR,
aVL and AVF leads, which has 50% larger signal than the addi-
tional limb leads.9,10 Later in 1944, Wilson proposed the use of
unipolar leads (V1-6) to study the potentials close to the heart.11
The previously described leads together form the traditional
12-lead ECG system consisting of I-III, aVR, aVL, aVF and V1-6.
For the purpose of measuring the QT interval either the traditional
12-lead system is used, where the limb leads are on the distal
extremities or the Mason-Likar electrode position12 (Figure 1.1
panel A) is used. The Mason-Likar system has the advantage,
over the standard 12-lead system, that the limb leads are placed
on the torso (instead of on the distal extremities) making it more
suitable for long term recordings.
The polarity, amplitude and morphology of the waveforms de-
pend on which lead is used. The lead depicted in Figure 1.1 panel
B is lead II, where the main ECG waveforms are positive. For
example, the R-wave is typically large and positive in lead II,
because the net current flow during ventricular excitation moves
from ventricular base to apex or top to bottom, which is in line
with the axis of lead II.
Concerning timing, the P-wave describes atrial depolarization,
and the QRS complex describes the ventricular depolarization.
Atrial repolarization occurs at the same time as ventricular de-
polarization (QRS complex), but its waveform is hidden by the
ventricular depolarization.
The ST-segment (roughly corresponding to phase 2 of the ac-
tion potential) and T-wave (roughly corresponding to phase 3 of
the action potential) characterize ventricular repolarization. Af-
ter the T-wave, a six waveform the so-called U-wave is sometimes
present, the meaning of which is still debated.13,14
4
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1.3 Measurement of the Heart Rate Corrected QT Interval
The QT interval is defined as the interval between the beginning
of the QRS complex and the end of the T-wave (Figure 1.2). The
measurement of the QT interval can be performed in any lead,
but lead II is often used. There is a small time difference between
leads, and the amplitude and shape of the waves varies as well.
Because of propagation effects, the end of the T-wave occurs later
in some leads than others. Therefore, when comparing QT interval
measurements within a subject it is crucial to use the same lead or
a global measurement.15 Global measurements of the QT interval
are defined as the beginning of the earliest QRS complex to the
last T-wave offset across leads.
Depolarization is rapid, so the rate of change in the ECG is
high throughout depolarization, making the QRS and QT onset
in most cases relatively unambiguous. However, repolarization is
a much more protracted process and the T-wave can merge into
the isoelectric baseline over 100ms or more, making the end of
the T-wave more arbitrarily defined. In addition, the U-wave,
whose origin is unclear,13,14 is variably included, and multiphasic
(“notched”) T-waves add further ambiguity. Thus, when looking
for untoward effects of drugs, it is as important to maintain con-
sistency in measuring the end of T-waves accurately as it is to
have consistency on the lead used. The end of the T-wave is often
defined as the point where the steepest descending tangent on the
downslope of the T-wave intersects the “zero-line”, which is also
called the isoelectric line,16 as shown in Figure 1.2.
The QT interval shortens as the heart rate increases.17,18 To
obtain a heart rate-independent assessment of repolarization, the
customary approach is to estimate what the QT interval would
be at a heart rate of 60 beats per minute (bpm) or, equivalently,
a RR interval of 1000ms.19 There are dozens of published for-
mulas for estimating the heart rate-corrected QT (QTc) interval
the most common of which is by Bazett:17 QTcB= QTp
RR
. How-
ever, it over-corrects the QT at low heart rates and under-corrects
at high heart rates.20 A better formula proposed by Fridericia is
5
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Figure 1.2 Example electrocardiogram (ECG) showing the differ-
ent waveforms and measurement of the QT interval using the tangent
methodology.16
QTcF= QT
RR1/3
.18 Fridericia showed originally that the factor was
closer to 0.36, as opposed to 1/3, but elected to use 1/3 due to
simplicity, and the approximation is still used in current practice
today.
Individuals have quite different QT/RR relationships which are
generally consistent over weeks or months.21 Therefore, the gold
standard, which is particularly important when a drug effects the
heart rate by more than a few beats per minute (bpm), is indi-
vidualized correction based upon the observed drug-free QT/RR
relationship.
Heart rate dependency for other ECG intervals, such as the PR
and QRS intervals22 and Tpeak-Tend 23 (duration of the descending
part of the T-wave) have been detected. However, these depen-
dencies are less important functionally than the one on QT since
the heart rate effects on the PR, QRS and Tpeak-Tend intervals are
much smaller compared to those of the QT interval. In addition
to using individualized QT correction for assessing drug-induced
effects, other techniques have also been proposed, that focuses on
comparing the QT at equivalent heart rates.24–26
6
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Short Long Short
Figure 1.3 Example of a case of torsade de pointes (TdP), which is
preceded by the typical short-long-short sequence (see text) recorded
in lead II (top) and Modified Chest Lead 1 or MCL1 (bottom). The
red arrow indicates the premature beat initiating TdP. Reprinted from
Roden,36 with permission from Massachusetts Medical Society.
The corrected QT interval is usually computed from the imme-
diately preceding RR interval, however adaptation of the QT to
heart rate takes approximately 2 to 3min.27,28 The lag in adapta-
tion can be accounted for by utilizing the history of RR intervals
to correct the QT interval for heart rate.29 A more common so-
lution is to only perform QT measurements when the heart rate
has been stable for several minutes.30
1.4 The Discovery of the Long QT Syndrome
In 1957, Jervell and Lange-Nielsen described a rare familial cardiac
syndrome that was linked to a prolonged QT interval, deafness
and sudden death.31 Later, Romano, et al., and Ward discovered
that there were other types of inherited long QT syndrome that
were not associated with deafness.32,33 Subsequently, Dessertenne
discovered that a prolonged QT interval could lead to a cardiac
arrhythmia which he called torsade de pointes (TdP). Torsade de
pointes is French for “twisting of the points” (Figure 1.3).34,35
Twisting of the QRS complex around the isoelectric line is one
of the characteristics of episodes of TdP.34 TdP is often initiated
by a short-long-short sequence, that is an extra ventricular beat,
followed by a compensatory pause, and then an arrhythmia initi-
ating ventricular extra beat (Figure 1.3, red arrow), which occurs
7
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within the previous QT interval.36,37 TdP is often self-terminating,
but in some cases it can degenerate into ventricular fibrillation and
cause sudden cardiac death. It is difficult to estimate the incidence
of TdP, because it can manifest itself as sudden cardiac death or
syncope, which is difficult to diagnose without accompanying ECG
documentation.
Several risk factors for TdP have been identified, such as fe-
male sex,38 congenital or drug-induced QT prolongation,36 hy-
pokalemia,39,40 or congestive heart failure.41 It is not known why
there is a difference between males and females in terms of risk
for TdP. However, it has been shown that when males enter pu-
berty their QTc shortens and increases again as men age.42 Sub-
sequently, elderly men and women, once more, have similar QTc
values.42 These QTc changes are inversely related to testosterone
levels in men.43 Moreover, differences in body size and pharma-
cokinetics between genders can result in a greater change in QTc
for women compared to men for a fixed dose.44 Interestingly, some
studies have observed a difference in sensitivity to drug-induced
QTc prolongation,45–48 but whether or not a difference between
genders exist has not been settled yet.44,49,50
Drug-induced TdP was first observed for quinidine in the 1920s
and was described as “quinidine syncope”.51 However, the rea-
son for the “quinidine syncope” was not discovered until 1964,
when Selzer and Wray reported a ventricular arrhythmia associ-
ated with “quinidine syncope”.52 It has since been proposed that
drug-induced TdP is likely caused by early after depolarizations
(EADs), which can arise through blockage of the hERG potassium
channel.53
Electrophysiological properties similar to those observed with
antiarrhythmics have also been observed for drugs where the car-
diac electrophysiological effect is not an intended effect of the
drug. One such case is the non-sedating antihistamine terfena-
dine. Between 1983 and 1991, 17 million new prescriptions were
made each year, but no concerns about cardiac issues were noticed
until 1989. In 1989 it was discovered that excessive concentrations
of terfenadine could lead to TdP,54 and a similar observation in a
8
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non-overdosed patient was made the following year.55 This led to
the Food and Drug Administration (FDA) reviewing reports in its
Spontaneous Reporting System pertaining to safety events associ-
ated with terfenadine. During this analysis it was discovered that
the majority of cases included patients unable to properly metab-
olize terfenadine because of concomitant use of ketoconazole, a
cytochrome P450 3A4 (CYP3A4) inhibitor.56
Subsequently, a “Dear Doctor” letter was issued in August
1990 to warn physicians about the terfenadine-ketoconazole inter-
action.56 Around the same time Woosley and colleagues reviewed
25 cases of TdP reported to the FDA’s Spontaneous Reporting
System.57 During the review of the reported cases of TdP, they
noted that terfenadine had similar characteristics to quinidine and
that in 11 of the cases the patients were taking drugs that inhibit
metabolism of terfenadine.57 They went on to evaluate the effects
of terfenadine on the hERG tail current in an in vitro assay and
confirmed that terfenadine reduces the hERG tail current.57
The discovery of terfenadine increasing the risk for develop-
ment of TdP (with an associated incidence of one per 28,500 to
57,000 prescriptions) led to the withdrawal of terfenadine. The
withdrawal came after fexofenadine, the active moiety and me-
tabolite of terfenadine, became available. Subsequently, other
drugs (with different structure and therapeutic indications) were
removed from the market because of their potential to delay car-
diac repolarization and cause TdP (Table 1.1).
1.5 Regulatory Response to Discovery of Cardiovascular
Effects from Non-Cardiovascular Drugs
The initial regulatory response to this apparent “pharmacoepide-
mic” included the release of a “points to consider” document for
assessment of the potential of drugs to cause QTc interval pro-
longation by the Committee for Proprietary Medicinal Products
(CPMP) of the European Union in 1997. The “points to consider”
document was followed by a Canadian draft in 2001 and the Health
Canada/USA draft in 2002. Later, the International Conference
9
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Table 1.1 Drugs withdrawn from the market due to risk for
torsade de pointes (TdP) (adapted from Stockbridge, et al.58).
Drug Year Therapeutic class
Prenylamine 1988 Antianginal
Lidoflazine 1989 Antianginal
Terodiline 1991 Antianginal / urinary in-
continence
Terfenadine 1998 Antihistamine
Sertindole 1998 Atypical anti-psychotic
Astemizole 1999 Antihistamine
Grepafloxacin 1999 Antibiotic
Cisapride 2000 Gastric prokinetic
Droperidol 2001 Tranquilizer / analgesic
Levacetylmethadol 2001 Methadone substitute
Dofetilide 2004 Atrial fibrillation
Thioridazine 2005 Antipsychotic
Clobutinol 2007 Antitussive
Dextropropxyphene 2009 Opiod analgesic
for Harmonisation (ICH) released two guideline documents: ICH
S7B59 and ICH E14.60 The ICH S7B describes preclinical testing
for effect on ventricular repolarization, and E14 describes clinical
testing for effect on QT interval.
The objective of the studies described in the ICH S7B is to
identify the potential of a drug and its active metabolites to delay
cardiac repolarization in relation to the therapeutic concentration.
This can be done by quantifying the drug-induced effect on iso-
lated cardiac ion currents, action potential parameters or in vivo
using animals.59
10
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1.6 Evaluation of Cardiovascular Effects using Preclinical
Assays
Drug-induced effects on isolated cardiac ion currents can be evalu-
ated for the hERG potassium current by measuring the reduction
of current with increasing drug concentration relative to a control.
This can be done using different cell systems such as isolated car-
diomyocytes (human or animal), where the activity of the other
cardiac ion channels are blocked ionically, pharmacologically or
reduced using special voltage clamp protocols.
Alternatively, heterologous expression systems using cloned hu-
man ion channels can be used (e.g., expressed in human embry-
onic kidney (HEK)61 or chinese hamster ovary (CHO) cells).59
While single channel recordings provide an evaluation of how a
drug interacts with different isolated channels, it can be difficult
to translate the findings to the whole heart. Moreover, differences
in protocols and testing environment, such as temperature, can
influence the results dramatically.62
Some of the limitations with the isolated ion channel assay
can be addressed by evaluating the drug-induced changes on ac-
tion potential parameters (e.g., using isolated Purkinje fiber cells
from animals). The isolated cells can then be exposed to increas-
ing concentrations of the drug and different parameters such as
the maximum slope of the upstroke (Vmax) or the action poten-
tial duration (APD) (APD from start until x% repolarization, e.g.
APD60, APD90, etc.) can be measured. The action potential pa-
rameter studies can help understand why a drug that reduces the
hERG tail current does not prolong the QTc interval.63 An exam-
ple of a drug that blocks the hERG potassium channel but does
not prolong action potential duration or QTc is verapamil. This
occurs because verapamil also blocks the L-type calcium channel,
which counteracts the effects of hERG potassium channel block.64
However, as with the isolated ion channel assay, there are limi-
tations that are important to remember. One of those limitations
is that autonomic nervous system effects are not captured with
isolated cells. In addition, effects on specialized pacemaker cells,
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Purkinje fibers, and gap junctions for intercellular communication
are nor present. Thus, an isolated cell might differ from the effect
on the whole heart.
Other types of cardiac preparations that can be used for in-
vestigating proarrhythmic effects include the ventricular wedge
model,65 which has been used to describe increased transmural
dispersion, a phenomenon proposed as being proarrhythmic. Al-
though the wedge model does provide useful insights into the
mechanism of the drug-induced effect, it is not the same as a
whole heart.66
Finally, the ICH S7B document describes the use of in vivo
studies in animals to capture the drug-induced effects on the car-
diovascular system. This can provide insights into how the drug
works on a complete system, unlike the two previously described
assays. Although an integrated analysis of the studies described
in the ICH S7B provides insight into the potential of a drug to
delay cardiac repolarization, there are still gaps in terms of how
to translate the findings to humans. One limitation is that the
expression of cardiac ion channels differs between humans and
animals, a limitation that also holds true for studying cardiomy-
ocytes isolated from animals.67 However, the results of the S7B
studies can provide insights into the mechanism and help better
understand the findings in humans.
Some of the limitations described above can be addressed by
studying induced-pluripotent stem cell (iPSC) derived cardiomy-
ocyte, a new and emerging platform for studying effects of drugs
on cardiac ion channels. The expression of cardiac ion channels in
iPSC derived cardiomyocytes is largely similar to adult cardiomy-
octes.68 However, there is a lower expression of the inward rectifier
(IK1) and the presence of pacemaker currents (If) resulting in spon-
taneous beating.68 While the resulting spontaneous beating makes
it easier to study them, as it removes the need for pacing, it means
that the cells are less adult like which could impact translation of
results. Interestingly, the iPSC derived cardiomyocyte cells carry
the genetic markup of the donor as has been shown by studies
of iPSC cells made from patients with congenital long QT syn-
12
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drome.69 Typical assays for studying the drug-induced effects on
iPSC derived cardiomyocytes are voltage sensitive dye (VSD)70,
microelectrode array (MEA)71 and impedance.72 These different
assays have their advantages and disadvantages. Specifically, the
VSD allows for recording action potentials, but at cost of using
a dye. In contrast, the MEA and impedance systems do not re-
quire the use of a dye, but do not provide a direct measurement of
the membrane potential but rather an aggregate signal. Overall,
the iPSC derived cardiomyocyte model is a new technology that
allows for studying drug-induced effects on cardiac ion channels,
which seem to complement the current ICH S7B paradigm.
1.7 The Thorough QT Study
The ICH E14 describes the so-called TQT study. The goal of this
study is to determine if the study drug or any of its active metabo-
lites has the potential to delay cardiac depolarization or to prolong
the QTc interval.60 This study is mandatory for almost all new
drugs and approved drugs for which a higher dose will be used for
a new indication. An exception to this rule is biopharmaceuticals
(biologics), as these can be exempt because of their inability to
interact with the hERG channel because of their size.73 To date,
more than 250 TQT study reports have been submitted to the
FDA for review,58 and the results from some of them have been
published.74
Study design
TQT studies are typically conducted using healthy subjects, as the
goal of the study is to determine if the study drug delays cardiac
repolarization, and this is generally not thought to be markedly
different in the patient population. Studies in healthy volunteers
can be smaller than studies in patients because there is less var-
iability introduced by coexisting morbidities and administration
of concomitant medications. Including male and female subjects
into the TQT study is recommended but not mandatory.60
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Not all drugs are appropriate for evaluation in healthy subject
volunteers (e.g., cytotoxic oncologic drugs), and for these drugs
a QT study would need to be conducted using actual patients,
which may not include a placebo or positive control.60,75 In such
settings, however, there is also a higher tolerance for risk and
an inability to detect small effects, due to the lack of a positive
control, is acceptable.
TQT studies employ either a parallel or cross-over design.60 A
cross-over design is often preferable because of its efficiency: each
subject serves as his or her own control, allowing for a smaller
sample size and a shorter study duration. For some drugs, notably
when the half-life is long or the drug requires titration, a cross-over
design is not feasible, and a parallel design must be used.
Cross-over studies typically include a pre-dose baseline assess-
ment, and it is important that subjects are randomized 1:1 to
treatment order, i.e., treatment A followed by B or vice-versa.76
The parallel study requires a time-matched baseline day for each
subject, to correct for diurnal variability in the QTc,77 which is
not necessary in the cross-over design, as the subject serves as
their own control.78
The doses of the drug explored in the TQT study should cover
at least the worst case exposure scenario, after accounting for
extrinsic (e.g., food) and intrinsic factors (e.g., renal or hepatic
impairment). The worst case exposure of both the study drug
and any active metabolites or metabolites associated with electro-
physiological effects must be addressed by the study.60
ICH E14 considers a prolongation of QTc of 5ms to be poten-
tially clinically relevant. In practice, that is assessed by assuring
that the upper bound of the effect is less than 10ms. This is only
about 1% of the duration of the normal QTc. Because such an ef-
fect might be excluded with a study that was insensitive to change,
all TQT studies should include a positive pharmacologic control.
The pharmacologic control is typically the fluoroquinolone mox-
ifloxacin, which has a well-characterized QTc prolonging effect79
of approximately 10 to 12ms for a single oral dose of 400mg.
The goal of including the positive control is to establish that the
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study is capable of detecting small changes in the QTc interval.
This is typically achieved by showing that increased QTc with
moxifloxacin follows the expected time course of moxifloxacin and
that the lower single-sided 95% confidence interval of the mean
increase in QTc for moxifloxacin is greater than 5ms.60,79 The
administration of the positive control can be open-label, as long
as the ECG interpretation is blinded and as long as the study
protocol is the same for all treatment arms.74,80
The QTc is measured on ECGs recorded at several time points
after dosing. The ECGs are obtained prior to drawing the blood
sample, to avoid autonomic effects associated with blood draw,
and after the subject has been supine for 5min to reduce effects
from changing heart rates.27,28
The sampling schedule should allow for capturing the QTc ef-
fect around maximum plasma levels of both the study drug and
major metabolites. In addition, the ECG sampling should allow
for capturing the time course of the effects of the positive phar-
macologic control.60,81
Typically, three ECGs, each 10 s in duration, are recorded at
each nominal time point and the average QTc measurement for
each time point is used in the analysis to reduce variability.82
Initially, these studies were conducted with a cart with an ECG
recorder, for which a 10 s record is the industry standard. How-
ever, by employing a continuous recording methodology one can
decrease the variability in the QTc measurement by extracting
ECGs with minimal noise in segments of stable heart rates.30 This
approach is now more common than are discrete short recordings.
Continuous recordings also permit post hoc decisions to supple-
ment originally planned data with additional time points.
The ICH E14 document requires two types of analysis of the
data from TQT studies. The first analysis is a central tendency
analysis (or analysis of time-dependent changes in baseline, and
placebo-corrected change (ΔΔ)). The other analysis is an out-
lier analysis, which is a summary table of the number of ECGs
that exceed some pre-specified thresholds for change in QTc as
well as absolute QTc values.60 In addition, to evaluate the drug-
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induced changes for the central tendency, the central tendency
analysis is also performed for the pharmacological positive control
as described earlier. Finally, a concentration dependent analysis
is often conducted to evaluate relationship between drug expo-
sure and changes in the QTc interval.83 These analyses typically
utilize linear mixed effects modeling to quantify the relationship
between plasma concentrations of the parent drug or metabolite,
and the baseline, and placebo-adjusted change (ΔΔ) in the QTc
interval.83
1.8 Beyond the Thorough QT Study
The TQT study has been successful in the sense that no drugs have
been removed after reaching the market because of risk of TdP af-
ter the introduction of the TQT.58 However, the TQT study is
a relatively expensive study, which can cost 2 to 4 million US
dollars.84 As such, there is an incentive to optimize the study.
Moreover, the focus on the QT interval and the hERG potas-
sium current might have led to abandonment of useful drugs.58
Different potential approaches for optimizing the TQT study or
improved methods to evaluate cardiac safety have been proposed,
including exploring the potential of doing early QT assessments,85
and evaluating new biomarkers of TdP risk that might be more
predictive than the QTc interval.86–88 Finally, there are efforts
to enhance preclinical evaluations, and potentially eliminate the
need for the TQT.89
Novel study ideas
As mentioned previously, the TQT study includes a pharmaco-
logical positive control, which is typically moxifloxacin. Besides
the potential ethical issue of administering a non-necessary drug,
the inclusion of a positive pharmacologic control is also inefficient
and not always possible. In single ascending dose (SAD) and mul-
tiple ascending dose (MAD) studies, the inclusion of a positive
control may not be feasible. Therefore, different approaches to
demonstrate assay sensitivity have been explored, including food
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effects,90 consistency of QTc measurements91 and postural ma-
neuvers92. Detecting the changes during meal intake or postural
maneuvers may not guarantee that the study has sensitivity for
all the tested data because of their brevity. Studying consistency
of the QTc measurements and the ability to detect circadian QTc
patterns might be better approaches as they allow for demon-
strating appropriate measurement over a longer time span, but so
far there has only been limited experience.91 This thesis focuses
specifically on evaluation of factors of ECG data quality, and how
they relate to the ability to demonstrate assay sensitivity in TQT
studies.
QT assessment early in drug development
Recently, it has been proposed that instead of conducting a TQT
study, it could be sufficient to perform a concentration dependent
analysis using data from SAD and MAD studies. In the current
paradigm, the TQT study is powered to detect a small difference
in the mean baseline, and placebo-adjusted (ΔΔ) change in QTc.
This type of analysis is not appropriate in early clinical studies,
because of the small number of subjects per cohort, typically six
on active drug and two on placebo. The early clinical studies
have, however, one distinct advantage over the TQT study, which
is that the dose in those studies will often exceed the worst-case
dose studied in the TQT study.93 The issue with reduced power
can be solved by using a concentration dependent analysis, which
will have sufficient power to detect a change in the QTc interval
around the threshold of regulatory concern (5ms),85 instead of
doing an analysis of effect by time, as in the TQT study.
A study was started in early 2014 to evaluate whether a SAD
or MAD study could detect QTc changes around the threshold of
regulatory concern.94 The study was a parallel study of six drugs,
five of which at the studied doses is expected to result in a pro-
longation of the QTc interval around the threshold of regulatory
concern (10ms), while the last drug has no effect on the QTc in-
terval.95 It was a successful study that showed it is possible to
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detect the QTc prolongation of each of the five positive drugs, but
not the negative drug. The findings support that a concentra-
tion dependent analysis can be used to detect QTc prolongation
around the threshold of regulatory concern in small sample sizes.
Novel ECG biomarkers
The two previously mentioned approaches deal with optimizing
the QTc evaluation and have the potential to reduce cost, however
they do not address the issue that QTc prolongation is a sensitive
but not specific biomarker of TdP risk. Commonly cited examples
of false positives include verapamil and ranolazine, both of which
are potent hERG potassium channel blockers with minimal effects
on the QTc interval and no associated risk for TdP. The low TdP
risk of these drugs supports that additional block of inward cur-
rents such as the calcium (verapamil) or late sodium current (ra-
nolazine), reduces the TdP risk associated with hERG potassium
channel block. It has been shown that blockage of these currents
prevents the occurrence of EADs,96,97 which likely causes TdP.
In addition, amiodarone is a drug with strong hERG potassium
channel block and substantial QTc prolongation (60ms prolon-
gation),98 but is associated with low TdP risk.99 Like verapamil
and ranolazine, amiodarone blocks multiple inward currents (L-
type calcium and late sodium), which can counteract the adverse
effects of hERG potassium channel block.
There are several research efforts to develop better biomarkers
for TdP risk. While some of these markers assess the concordance
between ventricular depolarization and repolarization,88,100 oth-
ers assess ventricular repolarization changes reflected in varying
T-wave morphology, such as T-wave notching, asymmetry and
flatness.86,87 Most new ECG biomarkers are typically evaluated
using data from the same study,101 that is the study of 160 and
320mg of oral d,l sotalol, thus limiting the ability for generaliza-
tion.102 That being said, the results are promising, and hopefully
future research will further elucidate usefulness of novel ECG pa-
rameters and their ability to differentiate between selective hERG
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potassium channel blocking drugs and hERG potassium channel
blocking drugs with additional inward current block which likely
have a lower risk for TdP. This thesis focuses specifically on as-
sessment of J-Tpeak and Tpeak-Tend for this purpose.
The biomarkers described in the previous paragraphs are all
generally assessed at stable heart rates to reduce the effects of
hysteresis (see section 1.3). Evaluation of the effects only at sta-
ble heart rates and removal of heart rate effects by applying heart
rate correction factors reduces the variability of the measurements
and allows for studying the drug-induced effects independent of
heart rate. However, by doing so, potentially valuable informa-
tion about proarrhythmic potential is removed. Specifically, eval-
uation of the beat-to-beat variability of the QT and the QT/RR
relationship can be viewed as clinical surrogates of action potential
instability and reverse use dependence (preferential prolongation
of QT at lower rates) respectively. Both of which are thought to
provide additional information about proarrhythmic potential in
addition to QTc. These strategies are part of the triangulation, re-
verse use-dependence, instability and dispersion (TRiAD) concept
proposed by Shah and Hondeghem.103 This thesis investigates the
clinical assessment of reverse use dependence and QT instability.
Comprehensive preclinical assessment
Besides ongoing research to improve how changes in cardiac repo-
larization are evaluated clinically, there is another area of active
research, in the preclinical space. A think tank sponsored by the
Cardiac Safety Research Consortium (CSRC), Health and Envi-
ronmental Sciences Institute (HESI) and the FDA met at the FDA
headquarters in July 2013, to discuss this new initiative which
is also called the Comprehensive in vitro Proarrhythmia Assay
(CiPA).89
Briefly, the goal of CiPA is to combine a more comprehensive
in vitro assessment, that is the functional effects on multiple hu-
man cardiac ion currents (IKr, INa, INa,L, ICa,L, IK1, Ito and IKs)
and use the data from the in vitro experiments to drive in sil-
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Figure 1.4 Overview of the Comprehensive in vitro Proarrhythmia
Assay (CiPA) paradigm. Reprinted from Sager, et al.,89 with permission
from Elsevier.
ico reconstructions of the entire cardiac action potential to assess
proarrhythmic risk (Figure 1.4).
It is envisioned that in vitro data on effects of drugs in isolated
human cardiac myocytes can be used to confirm the adequacy
of the voltage clamp data and in silico reconstructions, but such
model systems probably are not mature enough to substitute for
them at present.
Future of proarrhythmic risk assessment
The current cardiac safety paradigm as described in the ICH E14
guidance has been successful in the sense that the number of re-
ported TdP events for non-antiarrhythmic drugs has stabilized.
Besides the immediate obvious cost of the study design, the intro-
duction of the ICH E14 and ICH S7B guidances and the associated
focus on hERG potassium channel block and QTc prolongation
may have led to improper discontinuation of beneficial drugs.58
In particular, beneficial drugs such as amiodarone and verapamil
might not have been developed in today’s cardiac safety assess-
ment paradigm. Thus, there is a need to improve cardiac safety
assessment. This can hopefully be achieved by a combination
of enhanced assessment of drug-induced effects in early clinical
studies to confirm findings from enhanced preclinical assays as
proposed by CiPA.
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CHAPTER 2
Aims
The overall purpose of this thesis is to develop methods to discern
cardiac ion channel effects from electrocardiogram (ECG) record-
ings and evaluate these methods using data from two prospective
clinical trials. In addition, results from in vitro experiments (patch
clamp using over-expression systems) and computer simulations
are presented.
The first part of the thesis (Studies I and II) focuses on eval-
uation of factors associated with ECG data quality. The second
part (Studies III - VI) focuses on the relationship between different
ECG biomarkers and specific cardiac ion channel effects.
The specific aim for each study included in this thesis is outlined
below:
I. To test the hypothesis that adjustment of the QT interval
measurements based on ECG waveform similarity improves
the ability to detect the QTc prolongation associated with
moxifloxacin. In addition, this study evaluated if heart rate
stability predict the ability to detect the QTc prolongation
associated with moxifloxacin.
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II. To evaluate QTc quality metrics and how they relate to dif-
ferent factors that could influence study quality, including
QT measurement methodology, recorder type and reader
variability.
III. To test the hypothesis that an integrated analysis of ECG
intervals can identify drugs that selectively block the L-type
calcium channel (PR interval), peak sodium current (QRS
duration) or the human ether-à-go-go-related gene (hERG)
potassium channel (Tpeak-Tend interval).
IV. To test the hypothesis that selective hERG potassium chan-
nel blocking drugs prolong both J-Tpeakc and Tpeak-Tend, and
that drugs with additional inward current block (L-type cal-
cium or late sodium) preferentially prolong Tpeak-Tend.
V. To test the hypothesis that co-administration of a selective
late sodium current blocker reduces QTc interval prolonga-
tion associated with hERG potassium channel block, and
that the QTc interval shortening due to late sodium current
block is primarily driven by shortening of the J-Tpeakc inter-
val.
VI. To evaluate if it is possible to detect reverse use dependence
and QT interval instability associated with hERG potassium
channel block using postural maneuvers.
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Materials and Methods
3.1 Study Populations
Retrospective analysis of Thorough QT Studies (Studies I-III)
Studies I-III are based on retrospective analyses of digital elec-
trocardiograms (ECGs) from the Food and Drug Administration
(FDA) ECGWarehouse (http://www.ecgwarehouse.com), which
currently contains data from over 250 conducted thorough QT
(TQT) studies.58 Studies in the ECGWarehouse were performed
with informed consent and the respective protocols were reviewed
by the local Institutional Review Board (IRB). In addition, the
retrospective analyses described below were approved by the FDA
Research Involving Human Subjects Committee (RIHSC).
TQT studies from the ECGWarehouse submitted to the FDA
between January 2006 and December 2012 were considered for
inclusion in Studies I and II (N = 238). From this set TQT studies
that were completed before 2005 (n = 14), inappropriate design (n
= 21) or that did not include digital ECGs (n = 5) were excluded.
This resulted in a set of 179 TQT studies considered for inclu-
sion in Studies I and II. From this set 19, TQT studies failed to
demonstrate assay sensitivity and were included in the first part
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of the Study I, and 58 TQT studies included pharmacokinetic an-
alysis of moxifloxacin and were thus included in the second part
of Study I. In addition, 20 studies with multiple drug-free baseline
days were identified for inclusion in Study II.
Finally, TQT studies that included digital ECGs and had a
mean baseline, and placebo-adjusted (ΔΔ) change in the QTc
interval >10ms (n = 17) from the ECGWarehouse were included
in Study III. In addition, a set of random QTc studies that did
not meet this criteria (n = 17) were also included in Study III.
Prospective clinical trials (Studies IV-VI)
Studies IV through VI focuses on data from two FDA sponsored
clinical trials conducted at a phase I clinical research unit (Spauld-
ing Clinical Research, West Bend, WI, USA). The two prospective
clinical trials were reviewed by the FDA RIHSC as well as the local
IRB and all subjects gave written informed consent.
The two prospective trials included 22 healthy subjects each,
and similar inclusion and exclusion criteria as for TQT studies
were used.60 Briefly, the inclusion and exclusion criteria included:
no family history of congenital long QT syndrome as well as no
history of heart disease or unexplained episodes of syncope, be 18
to 35 years of age at the start of the study, weigh at least 50 kg and
have a body mass index between 18 to 27 kg/m2. In addition to
the typical exclusion criteria employed by TQT studies, subjects
with >10 ectopic beats during a 3 h ECG recording at screening
were also excluded.
ECGs in both prospective clinical studies were recorded using
continuous 24-hour 12-lead Holter recorders (Surveyor, Mortara
Instrument, Milwaukee, WI, USA) using the Mason-Likar config-
uration.12 The ECGs were recorded at 500Hz with an amplitude
resolution of 2:5 µV. In both trials, triplicate 10 s ECGs were ex-
tracted from the Holter recordings during supine rest with the
most stable heart rate and highest signal quality.30 ECGs from
both studies were analyzed in a semi-automatic fashion using pre-
viously developed software (see section 3.5).104,105
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In both studies post-dose blood samples samples were drawn
at the end of each nominal time point to enable pharmacokinetic
analysis. The blood samples were analyzed using a validated liq-
uid chromatography with tandem mass spectroscopy method by
Frontage Laboratories (Exton, Philadelphia, PA, USA).
Prospective clinical trial 1 (Studies IV and VI)
The first prospective clinical trial (SCR-002) was a five-way cross-
over study separated by a seven-day washout period. The pri-
mary endpoint of the study was to evaluate the ECG signature of
drugs with well known electrophysiological effects. Specifically, it
was hypothesized that human ether-à-go-go-related gene (hERG)
potassium channel block prolongs both the heart rate corrected
J-Tpeak (J-Tpeakc) and the Tpeak-Tend intervals. In addition, it was
hypothesized that addition of inward current block would primar-
ily shorten J-Tpeakc.
The study included 22 subjects, five replacements, and 20 sub-
jects were expected to complete. Based on sample-size calculations
proposed by Zhang and Machado106 the study was powered to de-
tect a change in 10ms, which based on the retrospective study of
34 drugs (Study III) was expected to be appropriate.
During each visit, the subjects would check-in the day before
dosing, and were fasting overnight. The study included dofetilide,
quinidine, ranolazine, verapamil and placebo. The drugs were
selected because they all have well characterized electrophysiogical
effects, and represent a group of drugs with high risk for torsade de
pointes (TdP) (500 µg dofetilide, 400mg quinidine) and low risk
for TdP (120mg verapamil, 1500mg ranolazine). The selected
doses were clinically used doses with the exception of ranolazine,
which was studied at 1500mg. The reason for the higher dose
of ranolazine was to achieve plasma concentrations more similar
to steady-state levels.107 The selected drugs allow for studying
the effects of selective hERG potassium channel block (dofetilide)
in contrast to hERG potassium channel blockers that also block
inward currents such as the L-type calcium (quinidine, verapamil)
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or late sodium current (ranolazine).
The drugs were administered in the morning of the treatment
day. Before drug administration and at 15 time points after dose
(0:5, 1, 1:5, 2, 2:5, 3, 3:5, 4, 5, 6, 7, 8, 12, 14 and 24 h post-dose)
the subjects were resting in a supine position for 10min, during
which ECGs were extracted as describe above.
In addition, at the pre-dose time point and at a six post-dose
time points (1, 2, 3, 4, 6 and 7 h) the subjects performed a series
of postural maneuvers: unsupported sitting and standing (5min
each at pre-dose, 2, 4 and 6 h post-dose) or unsupported sitting
and leg raises (5min each at 1, 3 and 7 h post-dose). The postural
maneuvers were performed to increase heart rate and allow for
analysis of rate dependent effects (Study VI).
At all post-dose time points after the postural maneuvers or
leg raises for the extended time points or the supine rest for the
other time points a blood sample was drawn for pharmacokinetic
analysis.
Prospective clinical trial 2 (Study V)
The second prospective trial (SCR-003, Balanced Ion Channel
Trial) was also a five-way cross-over study separated by a seven-
day washout. The primary end-point of the second clinical trial
was to test whether or not selective block of the late sodium cur-
rent by (mexiletine or lidocaine) could shorten QTc prolongation
resulting from block of the hERG potassium channel by dofetilide.
It was hypothesized that the shortening would be primarily due to
shortening of the J-Tpeakc interval. The secondary endpoint was
to evaluate whether or not L-type calcium channel block by dil-
tiazem could shorten drug-induced block of the hERG potassium
channel by moxifloxacin.
Prior studies suggested that administration of a late sodium
current blocker such as mexiletine108 and lidocaine109 would be
expected to shorten the QTc interval by 20 to 40ms. Based on
this, sample size calculations similar to the first study were carried
out resulting in an enrollment of 22 subjects, with five potential
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replacements, expecting 20 subjects to complete.
During each visit, doses were administered in the morning,
afternoon and in the evening. Each dosing period (morning, af-
ternoon and evening) started with an oral dosing of dofetilide,
mexiletine or placebo. After administration of the oral dose, an
intravenous dose of: lidocaine, moxifloxacin, diltiazem or placebo
was administered over 60min (loading dose) followed by a 30min
maintenance dose (Figure 3.1).
The choice of multiple doses throughout the day was to allow
for studying selective late sodium current block in the morning as
well as increasing doses of both late sodium current and hERG
potassium channel block throughout the day. In addition, this
design allowed for studying low and high doses of moxifloxacin as
well as moxifloxacin combined with diltiazem.
The specific doses were either selected based on our prior study
(dofetilide), to match highest studied doses (moxifloxacin), label
(diltiazem) or previous studies (mexiletine and lidocaine). In the
case of mexiletine a study that showed shortening of quinidine-
induced QTc prolongation,108 and for lidocaine a study showing
shortening of QTc in patients with congenital long QT type 3
(sodium channel defect) and healthy controls.109 All the intra-
venous doses were modified to allow for a 60min loading dose and
30min maintenance dose.
In contrast to the first clinical trial, oral dosing was performed
after food administration in the second clinical trial. The reason
for administering the doses under fed conditions was to minimize
gastrointestinal tract related adverse events following oral dosing
of one of the drugs (mexiletine).
ECGs were extracted at the pre-dose time point as well as at
four time points for each dosing interval (30, 60, 90, 120 min post
start of intravenous loading dose). Blood samples were drawn at
the end of the supine rest associated with each ECG extraction.
Similar to the first clinical trial, the subjects underwent a set of
postural maneuvers (5min unsupported sitting, and 5min stand-
ing) following the supine rest during each dosing period, but before
collection of blood samples.
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Figure 3.1 Overview of dosing for the second prospective trial for
each of the five treatment arms: dofetilide alone, dofetilide + mexile-
tine, dofetilide + lidocaine, placebo or moxifloxacin + diltiazem. IV:
Intravenous, Dof: Dofetilide, Mex: Mexiletine, Lido: Lidocaine, Mox:
Moxifloxacin, Dil: Diltiazem. Reprinted from Johannesen, et al.,110
with permission from John Wiley and Sons.
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Figure 3.2 Example of the result of application of the pattern match-
ing methodology by Hnatkova, et al.111 Applying the pattern matching
methodology for this electrocardiogram (ECG) changed the onset of the
QRS complex by 3ms and T-wave offset (original: Toriginal, adjusted:
Tpattern) by 46ms. Reprinted from Johannesen, et al.,112 with permis-
sion from Springer Science+Business Media.
3.2 Pattern Matching (Studies I and II)
There is no gold standard for measurement of the QT interval
on an ECG since the location of the fiducial points making up
the QT interval, onset of the QRS complex and T-wave offset
depends on the interpretation if the ECG. However, systematic
measurement of the QT interval is important as changes between
drug and placebo are compared. A methodology proposed by
Hnatkova, et al.,111 ensures consistent measurement of the QT
intervals by re-adjustment of the measurements based on pattern
matching. An example of application of the methodology is shown
in Figure 3.2.
The basis of the pattern matching methodology is to extract
the samples in a window around the onset of the QRS complex and
of T-wave offset separately in a global lead (e.g. vector magnitude
or root-mean-square lead) and align it with all other extracted
windows from the same subject. Afterwards, all the extracted
segments are compared to each other iteratively by taking one
segment and aligning all other segments to that one segment based
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on maximizing a cost function, e.g. cross-correlation. When the
maximum cross-correlation is achieved the location of the onset
of the QRS complex or T-wave offset in the segment the other
segments were aligned to is updated based on a weighted average
of the distance of each of the other segments to the first segment,
where the weight is based on the cost function. The procedure
is the then continued for all the other segments. This way the
location of the QRS complex or T-wave offset will converge to
some average location based on similarity to other waveforms.
This methodology has been shown using drug-free data to reduce
the variability of QTc.111
3.3 ECG Quality Metrics (Study II)
To evaluate quality of measurements of the QTc interval in TQT
studies, e.g. to serve as a replacement for the positive control, a
set of QTc quality metrics has been proposed.91 The concept be-
hind the quality metrics is to capture consistency in the QT/RR
relationship between visits as well as intra- and inter-subject dif-
ferences over time. This is done by computation of three types of
tests.
The first test covers intra-subject variation in the heart rate
corrected QT (QTc) interval, and is computed by the standard de-
viation of drug-free measurements of QTc per subject. The second
test quantifies the day-to-day variability of QTc measurements by
evaluating the difference per subject per time point using drug-free
data. Finally, the third test computes the day-to-day variability
per time point or average across time points of differences between
all subject combinations.
3.4 ECG Simulations (Study III)
Simulations of the effects of various amounts of L-type calcium
channel block combined with hERG potassium channel block was
performed using a combination of a model of the human ven-
tricular action potential, the O’Hara-Rudy model113 and the ac-
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O'Hara Rudy model ECGSIM model
25% hERG potassium
channel block
control
Compute body-surface 
potentials and ECG
V5
25% hERG potassium 
channel block
control
Relative to baseline change matched in ECGSIM
Relative to baseline change matched in ECGSIM
Apply changes throughout 
heart endo- and epicardium 
independently
Figure 3.3 Example of simulated human ether-à-go-go-related gene
(hERG) potassium channel block. The left panel shows a simulated ac-
tion potential (control: black dashed, hERG potassium channel block:
red) and the measurement of the relative (to control) changes in action
potential from the O’Hara-Rudy model.113 The relative changes from
the O’Hara-Rudy action potential are then applied to the action poten-
tial in ECGsim114 and a 12-lead electrocardiogram (ECG) is simulated.
Reprinted from Johannesen, et al.,118 with permission from John Wiley
and Sons.
tion potential-to-body surface ECG model (ECGsim, http://
www.ecgsim.org).114
In the first step the drug effect on the action potential was stud-
ied using the O’Hara-Rudy model using the “conductance block
model”,115 by reducing the maximum conductance of a current
by x percent. The effect of 25% hERG potassium channel block
or 25% reduction of the conductance relative to control is shown
in Figure 3.3, where the red line is after block of the hERG po-
tassium channel and the black dashed line is control.
Afterwards, changes in the action potential relative to control
was measured and applied uniformly to the action potentials in
the ECGsim model throughout the endo- and epicardium and the
12-lead ECG is computed using ECGsim.
Finally, the ECG intervals of interest (QT, J-Tpeak and Tpeak-
Tend) are measured on the simulated ECGs using an automatic
delineator.116,117
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3.5 Assessment of ECGs (Studies IV-VI)
The primary analysis of ECGs from the two prospective clinical
trials were performed on 10 s ECGs extracted during supine rest
based on signal-to-noise ratio and heart rate stability.30
The extracted 10 s ECGs were then preprocessed by first up-
sampling to 1 kHz using cubic spline interpolation. Subsequently
baseline wander was removed by estimating the baseline wander
using cubic splines fitted through a point in the PQ segment.119
From each 10 s ECG a median beat was created by aligning
each individual beat from the 10 s ECG on the R-peak and com-
puting the median sample-by-sample to form the median beat for
each lead.
Afterwards, the vectorcardiogram was constructed using the
Guldenring transform.120 Then, the magnitude of the resulting
X, Y and Z leads were computed to form the vector magnitude
lead (Figure 3.4). The vector magnitude lead represents a global
lead and measurement of the QT interval using this lead has been
shown to result in more consistent measurements.121
In Study IV the onset and offset of the QRS complex was
measured using lead II. The QRS onset and offset was located in
the Study V using a wavelet-based methodology using the vector
magnitude lead.104,116
The T-wave offset is then measured in the resulting vector mag-
nitude lead using the tangent method.16 The tangent method de-
fines the offset of the T-wave is the intersection between the steep-
est slope of the descending limb of the T-wave and the isoelectric
or “zero line”. An example is shown in Figure 3.4.
The peak of the T-wave was defined as location of the maxi-
mum of the T-wave. In the case of notched or flat T-waves the
peak was defined as the location of the first peak or in the middle
of the T-wave respectively.
In both prospective clinical trials ECG readers blinded to treat-
ment, time and subject information measured all ECG intervals.
For ECGs where the measurement of any fiducial point (onset and
offset of QRS, peak of T-wave or end of T-wave) was more than
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Figure 3.4 Example of assessment of the T-wave offset in the vec-
tor magnitude lead. First, the median beat from the 12-lead median
beat electrocardiogram (ECG) is used to construct the X,Y and Z
leads (vectorcardiogram) by applying the Guldenring transform.120 Af-
terwards, the magnitude of the vectorcardiogram is computed sample-
by-sample. Finally, the T-wave offset is located using the tangent
method.16 Reprinted from Johannesen, et al.,122 with permission from
John Wiley and Sons.
5ms different or there were disagreement about the presence of
notch or whether or not the T-wave was measurable, the ECGs
were re-assessed blinded to the reason for re-assessment and pre-
vious measurements. If the two readers disagreed after the second
read, a blinded expert ECG reader was consulted.
3.6 Holter Analysis (Study VI)
To facilitate analysis of beat-by-beat changes in the QT interval
and to quantify changes in the rate dependency of QT or markers
of QT interval instability (see section 3.7) a series of processing
steps was implemented (Figure 3.5).
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The steps for this process consists of:
I. Holter QRS detection:
a) Automatic detection of QRS complexes using a previ-
ously developed QRS detector.104
b) Adjudication of automatic delineation near windows of
interest starting 5min before supine rest and ending at
the end of the postural maneuvers using Holterlab.105
II. Extraction of non-overlapping 10 s ECG from periods of su-
pine rest and postural maneuvers.
III. Preprocessing of the extracted 10 s ECGs and generation of
median beats similar to the standard assessment of ECGs
(see section 3.5).
IV. Semi-automatic detection of the onset of the QRS complex
and T-wave offset:
a) Automatic determination of the onset of the QRS com-
plex and T-wave offset similar to the primary ECG as-
sessment (see section 3.5).
b) Application of pattern matching to the onset of the QRS
complex to ensure systematic measurements. This pro-
cess was necessary as the onset detector of the QRS was
not as reliable as the T-wave offset and application of
pattern matching reduced the overread burden signifi-
cantly.111
V. Project locations of fiducial points from median beats onto
the beats used to create the median, in the Holter recording,
using cross-correlation.123
3.7 Dynamic Repolarization Markers and Reverse Use
Dependence (Study VI)
Changes in the relationship between heart rate and the QT inter-
val were quantified by evaluating the linear relationship between
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Figure 3.5 Overview of the methodology used to measure beat-by-beat
QT/RR measurements, following detection and adjudication of QRS
detections. First step is to extract non-overlapping 10 s electrocardio-
grams (ECGs), and create representative median beats. Afterwards,
each median beat is annotated and pattern matching is applied to en-
sure consistent identification of the onset of the QRS complex and the
measurements are projected back onto the continuous ECG.
the square root of the preceding RR interval in seconds and the
QT interval in seconds as proposed by Okada and colleagues.124
An increase in the slope of this relationship indicates the presence
of reverse use dependence.
Several methodologies exist for quantifying changes in QT in-
terval variability as described in a recent systematic review by
Niemeijer and colleagues.125 In addition, analysis of QT variabil-
ity indices typically only include a few measures of QT interval
variability making it difficult to compare and contrast methods.125
As a result, three methods were included in this work:
• QT variability index (QTVI) as proposed by Berger et al.126
– QTVI = log10

QTv/QTm2
HRv/HRm2

• Median absolute deviation of QT (MADqt)
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– MADqt = median(jQTi  median(QT )j)
• Short term variability of QT (STVqt)
– STVqt =
n 1X
i=0
jQTi+1  QTij
n
p
2
These three methods were selected either because they had
been used to study drug-induced effects127 or quantify the beat-to-
beat variation in QT similar to methods used in preclinical studies.
It is worth noting that MADqt and STVqt are not corrected for
changes in heart rate but QTVI is.
In addition to considering three indices of QT interval vari-
ability, the indices are computed for each of the three different
maneuvers independently because a recent study by Hnatkova, et
al., suggests that measures of QT interval variability might depend
on postural maneuver.128
3.8 Statistical Analysis
As several ECG intervals exhibit heart rate effects, they have to
be corrected for heart rate before statistical analysis. However,
because only drugs without substantial heart rate changes were
studied, the QT interval was corrected using Fridericia’s correc-
tion,18 which is appropriate in the absence of substantial heart
rate changes.129
In addition to the QT interval, heart rate dependent changes
have also been observed for the J-Tpeak interval118 and minimal
heart rate effects near resting heart rates for PR, QRS and Tpeak-
Tend.22,23,118
The effect of heart rate on the J-Tpeak interval was modeled
using measurements from a subset of subjects (n = 431) with the
widest span in heart rate (55 to 75 bpm) using an exponential
model, similar to Bazett17 or Fridericia.18 This resulted in the
following correction equation for J-Tpeak:118
J-Tpeakc =
J-Tpeak
(RR/1000)0:58
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The other ECG intervals (PR, QRS, Tpeak-Tend) were not cor-
rected for heart rate.
Studies I and II
As there is no gold standard definition of the QT interval, the
impact of applying the pattern matching methodology to reduce
QT interval variability was evaluated by a linear mixed effects
model:
QTci;j = (+ i) + ( + i) conc+ 
Where QTci;j represents the jth baseline, and placebo-
adjusted (ΔΔ) QTc measurement from subject i,  and  is the
intercept and slope respectively. Subscripts i for  and  indicates
that it is the random effect for that subject.
In the described model above the residual represents the con-
sistency of the QTc measurements as moxifloxacin concentrations
are linearly correlated with changes in the QTc.130
This model was fitted for each study using PROC MIXED in
SAS 9.2 (SAS Institute, Cary, NC, USA). The residuals between
different methods for computing the QTc was then compared using
a paired t-test in R 2.15.3 (R Foundation for Statistical Comput-
ing, Vienna, Austria).
In both Studies I and Study II a Mann-Whitney test was used
to compare the intra-replicate heart rate (Study I) or QTc quality
metrics (Study II) by different groups using R.
Study III
Study III included the retrospective assessment of 34 TQT studies
on several ECG biomarkers: PR, QRS, Tpeak-Tend and QTc (see
section 3.1).
For the QTc interval the ICH E14 guidelines defines a threshold
of regulatory concern of 10ms,60 but for the other ECG intervals
no thresholds exist. To define a set of thresholds for all the studied
ECG intervals in the same way, the day-to-day variability (QTc
quality test 2, see section 3.3) was quantified using data from a
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set of 20 cross-over studies with multiple drug-free baseline days.
The day-to-day variability per study was summarized by taking
the average lower to upper bound of variability and taking the
maximum rounded absolute bound evaluated in R.131
Afterwards, if the maximum absolute effect of a drug by time
within the first 12 hours excluded the day-to-day variability for
each ECG biomarker it was considered to be significant. Of note,
the time point for different biomarkers were not forced to be the
same, as it is possible that different mechanisms are driving the
different biomarkers.
Lastly, Fisher’s exact test was used to evaluate the relationship
between block of a given cardiac ion channel (peak sodium, hERG
potassium or L-type calcium) and effects on PR, QRS, Tpeak-Tend
or QTc using R.
Studies IV-VI
Studies VI and V were based on two prospective clinical trials
(see section 3.1), which consisted of ECG measurements and drug
concentrations for each drug. The main analysis for the data from
these two studies were either a by-time or concentration dependent
analysis.
The by-time analysis modeled the QTc as a function of time,
treatment, time and treatment interaction, period and sequence
and a random effect on the intercept by subject using PROC
MIXED in SAS. Afterwards, the QTc by drug and treatment
was computed as the difference in the least squares means of treat-
ment minus placebo by time.
The concentration dependent analysis was performed using a
linear model as in the analysis of Study I (see section 3.8), allow-
ing each subject to have an individual intercept and slope. The
concentration dependent analysis was also performed using PROC
MIXED in SAS. The assumption of the linearity was evaluated us-
ing a visual predictive check by comparing the data binned into 10
bins (deciles) and overlaying the population prediction from the
model.
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The difference in the relationship between the J-Tpeakc and
Tpeak-Tend concentration dependent relationship (slope) was com-
pared by using a paired t-test on the individual slopes between
the two intervals using R.
The effect of mexiletine or lidocaine to reduce dofetilide in-
duced effects on repolarization was evaluated by computing the
difference of the least-squares estimates of mexiletine or lidocaine
+ dofetilide and the dofetilide arm. Similarly, the effect of dil-
tiazem on moxifloxacin was compared to evaluate the effect of
diltiazem to reduce moxifloxacin-induced QTc prolongation.
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CHAPTER 4
Results and Comments
4.1 Evaluation of Factors Influencing the Ability to Detect
Effect of Moxifloxacin (Study I)
Comparisons of different methodologies for computing the heart
rate corrected QT (QTc) interval and how it effects the residual
variability of a linear concentration QTc model (see section 3.8)
are shown in Figure 4.1. The analysis includes evaluation of four
different QTc calculations: data 1 (original QT/RR), data 2 (orig-
inal QT, average RR), data 3 (pattern adjusted QT, original RR)
and data 4 (pattern adjusted QT, average RR).
The use of average RR lowered the residual of the model com-
pared to the QT/RR measurements (data 1: 8:43 2:00ms versus
data 2: 8:23 1:88ms; P < 0.001). An even greater reduction of
the residual was achieved when the QT measurements were cor-
rected (data 3) compared to just averaging the RR measurements
(data 2: 7:55 1:86ms, data 3 versus data 2; P < 0.001). Lastly,
combining average RR with pattern adjusted measurements (data
4) led to a further decrease in the residual (data 4: 7:12 1:62ms,
data 4 versus data 3; P < 0.001).
This suggests that the residual is driven by reader variability,
as shown by a reduction in the residual after application of pat-
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Figure 4.1 Comparison of residual variability of linear-concentration
QTc models for four different QTc calculations: data 1 (original
QT/RR), data 2 (original QT, average RR), data 3 (pattern adjusted
QT, original RR) and data 4 (pattern adjusted QT and average RR).
Reprinted from Johannesen, et al.,112 with permission from Springer
Science+Business Media.
tern matching. In addition, a reduction in the residual was also
observed when using the average RR for the 10 s. It is, however,
worth noting that the original RR could either be the average
for 10 s or the average of three beats. Which one it is depends
on whether or not the QT interval was measured on the median
beat.
These findings are consistent with previous observations of re-
duction in intra-subject variability after applying pattern match-
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ing111,132 or averaging of the RR measurements.77 This supports
the notion that consistency of QT interval measurements and sta-
ble heart rates impacts the ability to detect the QTc prolongation
associated with moxifloxacin.
While these results support that pattern matching algorithms
are helpful to reduce reader variability, it is unknown how these
observations translate to cases where significant morphological
changes are present in the T-wave.
It is also worth noting that the intercept of the concentra-
tion QTc relationship tended to decrease after applying pattern
matching and averaging of the RR. This sugests that the inter-
cept could be an artifact of data variability (intercept: original
QT/RR 2:25 2:58ms and pattern adjusted QT and average RR:
1:68 1:84ms). Similarly, there was a slight increase in the slope
after applying pattern matching and averaging of the RR.
In addition, the intra-replicate heart rate range was evaluated
as a measure of study conduct and compared between studies that
were able to demonstrate assay sensitivity to studies that failed
to demonstrate assay sensitivity (Figure 4.2). This analysis shows
that studies that failed to detect the QTc prolongation associ-
ated with moxifloxacin had a higher variability in heart rate as
seen by the increased range of intra-replicate heart rates (origi-
nal RR:5:98 2:19 bpm versus 3:86 1:41 bpm and averaged RR:
5:60 2:42 bpm versus 3:47 1:13 bpm; P < 0.001 for both). This
is consistent with the previous findings that averaging RR mea-
surements improved the precision by lowering the residual of a
concentration QTc analysis. These results suggest that using the
median intra-replicate range of heart rates can serve as a study
quality metrics and likely reflects study conduct.
Moreover, studies that failed to demonstrate assay sensitiv-
ity also tend to have lower maximum concentrations compared
to studies with assay sensitivity (2:3 0:6 µg/mL (n = 61) versus
1:8 0:2 µg/mL (n = 4); P = 0.33). While pharmacokinetic infor-
mation for moxifloxacin was not available in all studies that failed
to demonstrate assay sensitivity, it seems plausible that reduced
concentrations of moxifloxacin would impact the ability to detect
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Figure 4.2 Comparison of the median intra-replicate heart rate be-
tween studies that detected the expected time-profile of moxifloxacin
(assay sensitivity) compared to studies that did not using original RR
(A) or 10 s average RR (B). Reprinted from Johannesen, et al.,112 with
permission from Springer Science+Business Media.
assay sensitivity as it reduces the magnitude of the QTc prolonga-
tion. With a reduced magnitude of QTc prolongation, the impact
of inconsistent QT measurements with unstable heart rates likely
has a greater impact.
4.2 Factors of ECG Data Quality in Thorough QT Studies
(Study II)
Evaluation of the impact of different QTc calculations and previ-
ously proposed QTc quality tests91 is shown in Figure 4.3. Similar
to the results from Study I shown in Figure 4.1, there is a reduc-
tion for all QTc quality metrics when applying pattern matching.
In addition, a slight improvement when combining pattern ad-
justed QT measurements with average RR measurements was ob-
served (data 1 versus data 4, P < 0.001 for all). These findings
support that the proposed QTc quality metrics, which quanti-
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Figure 4.3 Comparison of effect of different QTc calculations on pre-
viously proposed QTc quality metrics: data 1 (original QT/RR), data 2
(original QT, average RR), data 3 (pattern adjusted QT, original RR)
and data 4 (pattern adjusted QT and average RR). Reprinted from Jo-
hannesen, et al.,133 with permission from Springer Science+Business
Media.
fies not just intra-subject variability but also consistency of inter-
subject differences across time and periods, is influenced by reader
variability and heart rate variability.
A comparison of the QTc quality metrics from cross-over stud-
ies grouped by QT measurement methodology or recorder type is
shown in Table 4.1. The table shows that the QTc quality metrics
tend to be lower (more consistent QTc measurements) for studies
with semi-automatic QT measurements in comparison to studies
using manual QT measurements.
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Table
4.1
QTc
quality
test 91
valuesgrouped
by
protocolfactors.
Reprinted
from
Johannesen,etal., 133
with
perm
ission
from
SpringerScience+BusinessM
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This would suggest that semi-automatic QT measurements
provide more consistent measurements. How many QT measure-
ments that were corrected during the semi-automatic overread or
which criteria were used to determine if adjustment of a QT mea-
surement was necessary is not known so no definitive conclusion
can be made.
No differences were observed between studies using standard
electrocardiogram (ECG) recording methodology when compared
to studies that used continuous Holter recordings. This is in con-
trast to prior work by Badilini and colleagues,30 which suggested
that extracting ECGs from a Holter recording allows for obtaining
10 s ECGs of higher quality and more stable heart rates, leading to
less variable QTc measurements. One possible explanation for this
conflicting observation is that some of the studies using continu-
ous recording methodologies extracted ECGs at fixed time points
from the Holter, e.g. 1, 2 and 3min after supine rest, thus ignoring
the stability of the heart rate and the ECG signal quality.
Overall, these findings suggest that the proposed QTc quality
metrics capture consistency of QT measurements. In addition, the
evaluation of QTc quality metrics in a set of 20 cross-over studies
suggests that using semi-automatic QT measurement techniques
improves QT measurement consistency. It is, however, worth not-
ing that the sample size of this study was relatively small, par-
ticularly when the set of studies was split into different subsets
based on measurement methodology or recording methodology.
Moreover, for 11 of the studies there was no mentioning of the
specific measurement methodology in the study report and these
were labeled as unknown which could have influenced the results.
That being said, the concept of using intra- and intersubject sta-
bility of QTc measurements seems to have merit and how it can be
expanded to be applicable to studies without multiple drug-free
baseline days deserves further study.
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4.3 Retrospective Analysis of Drug-Induced ECG Patterns
(Study III)
This study evaluated the relationship between changes in differ-
ent ECG intervals and electrophysiological mechanisms: PR inter-
val (L-type calcium), QRS (peak sodium) and Tpeak-Tend (human
ether-à-go-go-related gene (hERG)). The relationship between the
previously proposed ECG intervals and cardiac ion channel effects
is shown in Figure 4.4.
All the drugs that had been shown preclinically to block the
L-type calcium (n = 4) prolonged the PR interval (Figure 4.4)
more than the day-to-day variability (5 ms). Similarly all drugs
that blocked the peak sodium current prolonged the QRS duration
(Figure 4.4) more than the day-to-day variability (3 ms), except
for one drug. The one exception is a peak sodium current blocker.
It was is not expected to prolong the QRS duration clinically as
it preferentially blocks the sodium channel in its inactivated state
and has similar disassociation kinetics to Vaughan Williams class
Ib antiarrythmics (e.g., lidocaine).
There was also good agreement (18/26) between hERG potas-
sium channel block and prolongation of the Tpeak-Tend interval.
However, there were a better agreement between prolongation of
the QTc interval and hERG potassium channel block (20/26). The
improved consistency with QTc interval prolongation and hERG
potassium channel block compared to Tpeak-Tend and hERG po-
tassium channel block is likely because prolongation of the QTc
interval is divided into Tpeak-Tend prolongation and QRS onset to
T-wave peak prolongation, thus reducing the signal.
Interestingly, evaluation of the concentration dependent rela-
tionship from drugs that are selective hERG potassium channel
blockers and multichannel blockers (Figure 4.5) showed that se-
lective hERG potassium channel block prolongs both the J-Tpeakc
interval as well as the Tpeak-Tend interval. In contrast, drugs that
block the hERG potassium channel as well as inward currents
(L-type calcium) showed no prolongation (drug 6) or shortening
(drug 11) of the J-Tpeakc interval.
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Figure 4.4 Relationship between maximum effect by-time (see sec-
tion 3.8) for drugs tested for L-type calcium channel block (A), peak
sodium current block (B) and human ether-à-go-go-related gene (hERG)
potassium channel block (C) and PR, QRS and Tpeak-Tend intervals re-
spectively. Reprinted from Johannesen, et al.,118 with permission from
John Wiley and Sons.
An example ECG of this observation is shown in the bottom
panel of Figure 4.5 where drug 6 (multichannel blocker) prolongs
the QTc interval overall but by shortening of J-Tpeakc and prolong-
ing of Tpeak-Tend. In contrast drug 7, a selective hERG potassium
channel blocker, prolongs both the J-Tpeakc and Tpeak-Tend inter-
vals. This suggest that hERG potassium channel block prolongs
both J-Tpeakc and Tpeak-Tend, and that Tpeak-Tend is a more specific
marker of hERG potassium channel block.
The impact of L-type calcium channel block on ECG sub-
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Figure 4.5 Top panel (A) shows the results of a concentration de-
pendent analysis for two drugs from the same class that block multi-
ple cardiac ion channels (drug 6, 11: human ether-à-go-go-related gene
(hERG), L-type calcium and sodium) on the left and a selective hERG
potassium channel blocker drug 7 on the right. The bottom panel (B)
shows an example electrocardiogram (ECG) from drug 6 (multichan-
nel blocker) and drug 7 (selective hERG potassium channel blocker).
Reprinted from Johannesen, et al.,118 with permission from John Wiley
and Sons.
intervals was studied in a simulation study (Figure 4.6). The
simulation study shows that increasing amount of L-type calcium
channel block reduced QT prolongation from hERG potassium
channel block by shortening of the J-Tpeak interval. This is consis-
tent with the observations in the clinical trials and supports the
use of the J-Tpeak interval as a marker of inward current block.
50
Improving Assessment of Cardiovascular Safety
−10
0
10
20
30
40
50
60
70
0% 5% 12.5% 25%
−10
0
10
20
30
40
50
60
70
0% 5% 12.5% 25%
−10
0
10
20
30
40
50
60
70
0% 5% 12.5% 25%
Increasing calcium 
channel block
Increasing calcium 
channel block
Increasing calcium 
channel block
Calcium channel block
0% 5% 12.5% 25%
hERG potassium channel block hERG potassium channel block hERG potassium channel block
Δ
J-
T p
ea
k (
m
s)
Δ
Q
T 
(m
s)
Δ
T p
ea
k-T
en
d (
m
s)
Figure 4.6 Results from a simulation study of varying amounts of
human ether-à-go-go-related gene (hERG) potassium channel block (0,
5, 12.5 and 25%) combined with either 0, 5, 12.5 and 25% block of the
L-type calcium channel on different intervals measured on the electro-
cardiogram (ECG): J-Tpeak, Tpeak-Tend and QT. Reprinted from Johan-
nesen, et al.,118 with permission from John Wiley and Sons.
The results of this combined retrospective analysis and simu-
lation study supports the use of the ECG subinterval J-Tpeakc to
detect the presence of inward current block. However, the risk for
torsade de pointes (TdP) for the studied drugs is not known and
only a small subset of the included drugs had been evaluated for
other cardiac ion channels than the hERG potassium channel. In
addition, the assessment of effects on cardiac ion channels varied
between the included drugs. Lastly, in the simulation study we
applied relative changes observed in simulations using the O’Hara-
Rudy model113 to action potentials in the heart-to-body-surface
ECG simulator ECGsim,114 which is a simplification and has its
limitations and assumptions.
4.4 Differentiating Selective hERG Potassium Channel Block
from Multichannel Block (Study IV)
A prospective clinical trial of 22 healthy volunteers (11 female)
was conducted to prospectively study the ECG signatures of four
drugs: dofetilide, quinidine, ranolazine and verapamil. The con-
centration dependent relationships are shown in Figure 4.7.
The concentration dependent analysis of dofetilide showed an
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Figure 4.7 Concentration dependent analysis of QTc (gray), J-Tpeakc
(orange) and Tpeak-Tend (blue) for a selective human ether-à-go-go-
related gene (hERG) potassium channel blocker (A, dofetilide) and
hERG potassium channel blockers that block either the L-type calcium
channel (B, quinidine; C, verapamil) or the late sodium current (D, ra-
nolazine). Reprinted from Johannesen, et al.,122 with permission from
John Wiley and Sons.
equal prolongation of both J-Tpeakc and Tpeak-Tend (J-Tpeakc ver-
sus Tpeak-Tend P = 0.89). These observations are consistent with
those in Study III, that selective hERG potassium channel block-
ers prolong both J-Tpeakc and Tpeak-Tend.
In contrast, quinidine prolonged the QTc similarly to dofet-
ilide (dofetilide: 79:3ms (95% confidence interval (CI): 72:2 to
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86:3ms); quinidine: 78:1ms (95% CI: 70:9 to 85:2ms)), but quini-
dine preferentially prolonged the Tpeak-Tend interval (J-Tpeakc ver-
sus Tpeak-Tend, P = 0.025). This observation is consistent with the
electrophysiological mechanism of quinidine at the studied drug
concentrations, where it is expected to block both the hERG po-
tassium channel and the L-type calcium channel.
The QTc prolongation observed with ranolazine was entirely
due to prolongation of the Tpeak-Tend interval (J-Tpeakc versus
Tpeak-Tend P < 0.001). Thus, supporting that the J-Tpeakc in-
terval is influenced not only by hERG potassium channel block
but also inward current block. Specifically, that ranolazine’s late
sodium current block shortened J-Tpeakc while ranolazine’s hERG
potassium channel block prolonged J-Tpeakc resulting in no net
change.
No changes in QTc, J-Tpeakc and Tpeak-Tend were observed with
verapamil, likely due to a balance of hERG potassium channel and
L-type calcium channel block. A significant increase in the PR in-
terval (32:1ms (95% CI: 26:7 to 37:4ms; P < 0.001)) was observed
after verapamil administration, suggesting the administered dose
was high enough to elicit an electrophysiological response.
The findings of this study confirm the hypothesis that hERG
potassium channel block prolongs both J-Tpeakc and Tpeak-Tend,
and inward current block (L-type calcium or late sodium) pref-
erentially shortens the J-Tpeakc interval. These observations are
similar to those made for electrolyte abnormalities134 and genetic
abnormalities.135 Specifically, abnormalities in the hERG potas-
sium channel (long QT type 2)135 or hypokalemia result in a pro-
longation of both J-Tpeakc and Tpeak-Tend as well changes in the
T-wave136,137 similar to the observations with hERG potassium
channel block in this study.
In contrast, hypocalcemia has been shown to prolong the QT
interval without T-wave changes (via prolongation of the ST-
segment),134 and hypercalcemia shortens the action potential akin
to L-type calcium channel block.138 Similarly, abnormalities in the
sodium channel associated with long QT syndrome type 3 prolong
the QT interval without changes in the T-wave.135
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Changes in the PR interval were only observed after admin-
istration of verapamil, as previously noted, but no changes were
observed with quinidine which is expected based on the L-type
calcium channel block associated with quinidine. This is likely
due to the autonomic effects of quinidine.139 A slight change in
QRS was observed for ranolazine (2:7ms (95% CI: 0:5 to 4:9ms;
P = 0.018) and verapamil (2:6ms (95% CI: 0:4 to 4:8ms; P =
0.020)). Finally, an increase in heart rate was observed for both
quinidine (9:4 bpm (95% CI: 6:4 to 12:4 bpm; P < 0.001)) and
verapamil (9:8 bpm (95% CI: 6:8 to 12:9 bpm; P < 0.001)). In ad-
dition, a slight increase in heart rate was observed for ranolazine
(4:2 bpm (95% CI: 1:2 to 7:2 bpm; P = 0.007)).
Dofetilide and quinidine were both associated with substan-
tial QTc interval prolongation and changes in the morphology of
the T-wave.140 This makes determination of the peak of the T-
wave and end of the T-wave difficult. Two independent reviewers
agreed, however, in 98:6% of the ECGs (less than 5ms, or pres-
ence of notch). This suggests, that despite the significant changes
in morphology that the measurements of the ECG intervals were
consistent. In addition, quinidine and verapamil increased the
heart rate which confounded the use of a population-based cor-
rection, such as Fridericia.18,129 However, it is unlikely that the
differences between J-Tpeakc and Tpeak-Tend are due to the heart
rate effects of quinidine. Moreover, a slight increase in QTc for
verapamil may have been missed due to heart rate effects.
4.5 Late Sodium Current Block for Drug-Induced Long QT
(Study V)
Following the first prospective clinical trial described in the pre-
vious section, a second prospective clinical trial was conducted
to evaluate the ability of late sodium current block (mexiletine,
lidocaine) or calcium channel block (diltiazem) to shorten QTc
prolongation associated with hERG potassium channel block (do-
fetilide, moxifloxacin).
Similar to the results of the first prospective clinical trial, do-
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Figure 4.8 The top row of panels show the time-dependent effects on
baseline, and placebo-adjusted changes (ΔΔ) in QTc (black) or concen-
tration (green: dofetilide, blue: mexiletine/lidocaine) for the dofetilide
alone arm (A), mexiletine + dofetilide arm (B) or lidocaine + dofetilide
arm (C). Representative electrocardiograms (ECGs) examples from the
same subjects are shown in panel (D). Panels E and F show the differ-
ence in the changes from baseline between the dofetilide alone arm and
the mexiletine + dofetilide and lidocaine + dofetilide arms for (blue:
QTc, black: J-Tpeakc, orange: Tpeak-Tend). Reprinted from Johannesen,
et al.,110 with permission from John Wiley and Sons.
fetilide dosing resulted in prolongation of the QTc interval in
the evening (39:1ms (95% CI: 33:9 to 44:4ms; P < 0.001) Fig-
ure 4.8) that was split between prolongation of the J-Tpeakc in-
terval (24:0ms (95% CI: 19:2 to 28:9ms; P < 0.001)) and the
Tpeak-Tend interval (16:5ms (95% CI: 11:7 to 21:3ms; P < 0.001)).
The slightly increased J-Tpeakc over Tpeak-Tend is consistent
with the relative effects between the two intervals for lower con-
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centrations of dofetilide observed in the first prospective clinical
trial (Figure 4.7). This suggests that there is not necessarily a per-
fect balance in the increases in the two intervals for weak selective
hERG potassium channel blockers.
Interestingly, in the morning when a selective late sodium cur-
rent blocker was administered by itself, the QTc interval was
changed by ( 10:6ms (95% CI:  15:8 to  5:4ms; P < 0.001))
with mexiletine and a change in the QTc interval of ( 6:6ms (95%
CI:  15:8 to  2:4ms; P = 0.005)) with lidocaine. The shortening
of the QTc interval was due to shortening of the J-Tpeakc interval
(mexiletine:  9:3ms (95% CI:  14:1 to  4:6ms; P < 0.001); li-
docaine:  6:2ms (95% CI:  11:0 to  1:4ms; P = 0.012)), and no
changes in the Tpeak-Tend interval (mexiletine: P = 0.85, lidocaine:
P = 0.97).
This is consistent with the effects observed with ranolazine and
other drugs thought to block the late sodium current as well as the
effects of lidocaine and tocainide in long QT type 3 patients.109
In the afternoon and in the evening when the selective late
sodium current blocker was coadministered with dofetilide the
QTc was shortened in a dose-dependent fashion (Figure 4.8). The
shortening of the QTc interval was due to by shortening of the J-
Tpeakc interval (mexiletine:  23:2ms (95% CI:  28:0 to  18:3ms;
P < 0.001); lidocaine  20:5ms (95% CI:  25:5 to  15:5ms; P <
0.001)). Thus, resulting in a similar ECG signature as observed
with ranolazine in the first prospective clinical trial.
An example of an ECG is shown in Figure 4.8 (panel D), where
the QTc is prolonged by 40ms after dofetilide, and the T-wave is
flatter and asymmetric. After co-administration with mexiletine
or lidocaine, the dofetilide-induced QTc prolongation of 40ms
is shortened by 40ms for mexiletine or 30ms for lidocaine. In
addition, the mexiletine ECG shows signs of normalized T-wave
morphology.
When evaluating the plasma concentrations from the study
there was a slight increase in the plasma concentrations of dofet-
ilide when co-administered with mexiletine (1:8 0:3 vs 1:5 0:3
ng/mL, P < 0.001) or lidocaine (1:80:4 vs 1:50:3, P = 0.068).
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Figure 4.9 Differences between the changes in QTc (left panel), J-
Tpeakc (middle panel) or Tpeak-Tend (right panel) for dofetilide alone
(A) or moxifloxacin alone (B) represented by the line and shaded area
compared to dofetilide + mexiletine (A, red), dofetilide + lidocaine (A,
blue) or moxifloxacin + diltiazem (B, red). Reprinted from Johannesen,
et al.,110 with permission from John Wiley and Sons.
To account for these differences in the analysis of the effect of
mexiletine or lidocaine, a concentration dependent analysis was
also performed (Figure 4.9), which confirmed what was observed
in the time-dependent analysis (Figure 4.8).
Similarly, the plasma concentrations were higher in the evening
compared to the afternoon for moxifloxacin which is accounted for
in the concentration dependent analysis (Figure 4.9). Unexpect-
edly, no shortening of the QTc interval or the J-Tpeakc interval was
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Figure 4.10 Effects of moxifloxacin on four different cardiac ion chan-
nel or currents (red: IKr, green: INa,L, blue: ICa,L or purple: IKs). The
black error bars represent human ether-à-go-go-related gene (hERG) ef-
fect of the moxifloxacin M2 metabolite. The error bars represent mean
 standard error and the lines are the result of fitting a sigmoidal line
through the raw data points. Reprinted from Johannesen, et al.,110 with
permission from John Wiley and Sons.
observed when moxifloxacin was co-administered with diltiazem,
a L-type calcium channel blocker. This could be due to a poten-
tial accumulation of the M2 metabolite of moxifloxacin which also
blocks the hERG potassium channel (Figure 4.10). Additionally,
moxifloxacin also blocks the slow potassium current (IKs), the ef-
fect of which could be enhanced by diltiazem-triggered autonomic
changes and confound the analysis (Figure 4.10).
4.6 Drug-Induced Reverse Use Dependence and QT
Variability (Study VI)
Using the data from the postural maneuvers in the first prospec-
tive clinical trial (Study IV), changes in the QT/RR relationship
or QT interval dynamicity were evaluated.
This relationship is summarized for all subjects in Figure 4.11,
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Figure 4.11 Time-course of the baseline, and placebo-adjusted changes
(ΔΔ) for the slope of the QT/RR relationship (see section 3.7) for do-
fetilide, quinidine, ranolazine and verapamil.
which shows that quinidine was the only drug that increased the
relationship and caused reverse use dependence (P < 0.001).
Reverse use dependence has previously been shown for dofeti-
lide124,141, which was not observed in this study (P = 0.18). Pre-
vious studies,124,141 however, used a higher dose of dofetilide (250
and 750 µg twice daily compared to single dose of 500 µg), which
may explain the discrepancy.
It is, however, unlikely that the lower dose is the only explana-
tion as a study by Lande and colleagues showed that a single dose
of 500 µg dofetilide142 increased the slope of the QT/RR relation-
ship. However, methodological differences exist between the study
by Lande, et al., and the current study. Most notably, that the
study by Lande et al. only included all QT measurements with
stable heart rates around a 4 h window whereas in the current
59
Lars Johannesen
study beat-by-beat measurements were performed.
Cappato and colleagues143 only observed a change in the re-
lationship for quinidine after complete autonomic blockade. By
comparison, this study found a change without autonomic block-
ade (0:12 (95% CI: 0:05 to 0:19 ; P < 0.001)), likely a result of
the longer RR intervals compared to those studied by Cappato et
al. (RR: 400 to 600ms versus RR: 600 to 1000ms).
Interestingly, quinidine caused an increase in the slope of the
relationship which was not observed with dofetilide (Figure 4.11),
despite causing equal amounts of QTc prolongation (80ms) at
the studied doses. These differences could potentially be explained
by a difference in the hERG potassium channel block mecha-
nism,144 difference in hERG potassium channel block potency,140
or autonomic effects of quinidine.
The lack of changes in the QT/RR relationship for ranolazine
(P = 0.065) is consistent with in vitro observations that block
of the late sodium current could normalize the QT/RR relation-
ship.145 Similar observations were also made for mexiletine in a
patient with Timothy syndrome (L-type calcium channel abnor-
malities).146
No changes in the QT/RR relationship were observed for vera-
pamil (P = 0.47) in this study. However, a study of verapamil in
patients with paroxysmal atrioventricular nodal reentrant tachy-
cardia had a slight reduction of the slope of the QT/RR rela-
tionship.147 This discordance could be due to methodological dif-
ferences (ambulatory recordings vs Holter extraction for periods
of postural maneuvers), dosing (effects following single dose com-
pared to multiple dosing) or QT measurement methodology.
Interestingly, the study by Fauchier and colleagues with ver-
apamil in patients observed a more profound change in the rela-
tionship between RR and Q-Tpeak, which in the absence of QRS
changes is similar to the J-Tpeak/RR relationship. This is consis-
tent with Study III and IV, suggesting greater influence of L-type
calcium on the J-Tpeak interval.
The drug-induced effects on different QT interval indices either
accounting for heart rate (QT variability index (QTVI)) or not
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Figure 4.12 Time-course of the baseline, and placebo-adjusted changes
(ΔΔ) for different methods of quantifying the variability in QT and
RR (see section 3.7) for dofetilide (gray), quinidine (orange), ranolazine
(blue) and verapamil (green) during supine rest (first row), unsupported
sitting (middle row) or standing (bottom row).
accounting for rate (median absolute deviation of QT (MADqt),
short term variability of QT (STVqt)) was also evaluated for each
of the three postural maneuvers and the results are shown in Fig-
ure 4.12.
Figure 4.12 shows an increase in the different variability indices
for dofetilide and quinidine (P < 0.001 for all) that tend to be
maximized near the maximum drug concentrations (2 to 4 h). In
addition, an increase was also observed for verapamil near the time
of maximum verapamil concentration (1 h), which was largest for
QTVI in the supine and standing positions (P < 0.001).
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These observations are similar to those for intravenous co-
caine127 (IKr blocker with autonomic effects) and sertindole148 (IKr
blocker).
The changes are larger for standing and unsupported sitting
compared to supine, supporting that evaluation of variability of
the QT and RR intervals for different postural maneuvers should
not be combined.128
Interestingly, the results of this study suggest that QT variabil-
ity assessed using beat-by-beat measurements is more sensitive to
drug-induced effects than the slope of the QT/RR relationship.
This could be due to using beat-by-beat measurements of QT
and RR. Because, while the beat-by-beat measurements contain
information relevant to detection of changes in QT interval dy-
namicity, it likely adds noise to the assessment of rate dependent
changes.142
However, measurement of the QT interval on a beat-by-beat
basis, as needed for assessment of QT interval dynamicity, is not
always practical and susceptible to measurement error. Alterna-
tively, assessment of the QT/RR relationship could be performed
using limited data from stable beats as proposed by Lande and
colleagues.142 However, the inclusion of only stable beats necessi-
tates the use of a wider time window, which reduces the ability to
link the effects with drug concentrations.
Finally, while both methodologies explored in Study VI detect
changes in QT interval dynamicity associated with strong hERG
potassium channel block, they do not appear to be as sensitive
and specific to detect mild hERG potassium channel block and
detect the presence of multichannel block.
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CHAPTER 5
Conclusions
The studies in this thesis suggest that by evaluation of the J-Tpeakc
and Tpeak-Tend intervals it is possible to differentiate between selec-
tive human ether-à-go-go-related gene (hERG) potassium channel
blockers with or without additional inward current block (L-type
calcium or late sodium). Detection of additional inward current
block is relevant to differentiate between drugs with high risk for
torsade de pointes (TdP) such as dofetilide (selective hERG po-
tassium channel blocker) in contrast to low TdP risk such as ra-
nolazine (multichannel blocker). In addition, work in this thesis
suggests that the most important markers of electrocardiogram
(ECG) data quality are reader variability and heart rate stability,
a surrogate of study conduct.
The major conclusions for each study were:
I. The ability to detect QTc interval prolongation associated
with moxifloxacin is mostly influenced by QT reader vari-
ability and stability of the heart rate.
II. ECG quality metrics focusing on intra- and intersubject dif-
ferences of QTc are influenced by reader variability and QT
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measurement methodology. No differences were observed be-
tween standard 12-lead ECGs and ECGs from continuous
recordings, likely due to extraction methodology.
III. Drugs that only block the hERG potassium channel prolong
the QTc interval as well as the J-Tpeakc and Tpeak-Tend inter-
val. In contrast, drugs that block the L-type calcium channel
and/or late sodium current in addition to the hERG potas-
sium channel show preferential prolongation of Tpeak-Tend,
and potential shortening of the J-Tpeakc interval.
IV. The observed ECG patterns of Study III were prospectively
confirmed in a clinical trial of four drugs that are either selec-
tive hERG potassium channel blockers (dofetilide) or multi-
channel blockers: L-type calcium (quinidine and verapamil)
or late sodium (ranolazine).
V. Co-administration of a selective late sodium current blocker
shortens drug-induced QTc prolongation of dofetilide result-
ing from hERG potassium channel block. In addition, the
QTc shortening is entirely driven by shortening of the J-
Tpeakc interval consistent with Studies III and IV.
VI. hERG potassium channel block causes reverse use depen-
dence and instability of the QT interval, which can be de-
tected by using postural maneuvers. In addition, markers of
QT interval variability might be more sensitive than changes
in the QT/RR relationship.
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